Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 54

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 54
---
 carrying value which approximates fair value.

5.
ACCRUED EXPENSES

Accrued
expenses consist of the following as of:

 SCHEDULE OF ACCRUED EXPENSES

    July
    31,  
    October
    31, 

    2025  
    2024 

    (in
    thousands) 
  
    Payroll
    and related expenses 
    $865  
    $1,126 
  
    Accrued
    royalty and contingent legal fees 
     626  
     626 
  
    Accrued
    other 
     260  
     194 
  
    Accrued
    expenses 
    $1,751  
    $1,946 

6.
NET LOSS PER SHARE OF COMMON STOCK

Basic
net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares
outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number
of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented
is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this
reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2025 and 2024, were stock options to purchase
13,462,377 shares and 12,342,094 shares, respectively, and warrants to purchase 300,000 shares and 300,000 shares, respectively.

7.
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In
November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, to provide more disaggregated expense information about a public entity’s reportable segments. The amendments in this
update should be applied retrospectively and are effective for fiscal years beginning after December 15, 2023, and interim periods beginning
after December 15, 2024. We are currently evaluating the impact of this guidance on our consolidated financial statements and related
disclosures.

In
December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to